Menstrual blood-derived stem cells

Human menstrual fluid stem cells.

Phase of research

Potential treatment - clinical evidence

How it helps

Other treatment

Drug status


Supporting references
Contradictory references
AI-suggested references
Clinical trials

General information

Menstrual blood-derived stem cells (MenSCs) are isolated from human menstrual fluid. The cells express canonical mesenchymal stem cell markers and do not express hematopoietic stem cell markers. MenSCs can differentiate into adipocytes, osteocytes or chondrocytes under proper conditions. They actively involved in paracrine signalling and have immunomodulatory properties (Chen et al., 2019a). Inherent properties of MenSCs make them an object of research interest in the field of regenerative medicine. Their clinical potential has been addressed in the case of various health conditions including acute lung injury, Alzheimer’s disease, Asherman syndrome, cutaneous wound, diabetes, Duchenne muscular dystrophy, endometriosis, liver disease, myocardial infarction, neurodegenerative diseases, ovarian-related disease, or stroke (Chen et al., 2019b).


MenSCs; endometrial regenerative cells; menstrual blood stem cells


Supporting references

Link Tested on Impact factor Notes Publication date
Human menstrual blood-derived stem cells as immunoregulatory therapy in COVID-19: A case report and review of the literature
Stem cells Cell-based therapy Case report Mixed substance
A patient 1.34

Clinical improvement observed after treatment in the case of a patient with severe pulmonary injury caused by COVID-19. Sample size: 1. 


AI-suggested references

Clinical trials

ID Title Status Phase Start date Completion date
NCT05019287 Menstrual Blood Stem Cells in Severe Covid-19 Completed Phase 1|Phase 2 Apr/17/2021 Jun/09/2021
  • Alternative id - 990308-026|99/3436
  • Interventions - Biological: Allogeneic human menstrual blood stem cells secretome|Other: Intravenous saline injection
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Avicenna Research Institute, Tehran, Iran, Islamic Republic of
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 29
  • Age - 25 Years to 75 Years   (Adult, Older Adult)
  • Outcome measures - Adverse reactions incidence|Time to clinical improvement|Assessment of serum CRP (mg/L) levels|Assessment of serum LDH (U/L) levels|Assessment of serum Ferritin (ng/ml) levels|Assessment of serum D-dimer (microgr/ml) levels|Immunological changes on CD4+ T and CD8+ T|Lung Involvement|Changes in Inflammatory cytokine IL 6|Changes in anti-Inflammatory cytokine IL10